$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh

$plsh Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028898 Filed on August 15, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$347.9K	$399.1K	$469.5K
YoY Change	-5.02%	-14.98%	49.75%
Cost Of Revenue	$201.2K	$196.3K	$331.5K
YoY Change	-36.9%	-40.78%	33.32%
Gross Profit	$146.6K	$202.8K	$138.0K
YoY Change	209.81%	47.0%	112.76%
Gross Profit Margin	42.15%	50.81%	29.39%
Selling, General & Admin	$276.7K	$145.2K	$204.7K
YoY Change	5.82%	-29.06%	-67.05%
% of Gross Profit	188.74%	71.6%	148.35%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$424.0K	$422.7K	$409.9K
YoY Change	0.56%	3.13%	-10.95%
% of Gross Profit	289.21%	208.43%	297.09%
Operating Expenses	$1.561M	$1.277M	$1.378M
YoY Change	8.68%	-7.33%	-8.4%
Operating Profit	-$1.414M	-$1.074M	-$1.240M
YoY Change	1.83%	-13.38%	-13.85%
Interest Expense	$396.6K	$366.9K	$570.0K
YoY Change	-33.67%	-35.62%	100.43%
% of Operating Profit
Other Income/Expense, Net	-$737.0K	-$790.1K	-$721.8K
YoY Change	-43.53%	9.47%	-149.21%
Pretax Income	-$2.151M	-$1.864M	-$1.962M
YoY Change	-20.15%	-4.97%	-7308.79%
Income Tax
% Of Pretax Income
Net Earnings	-$2.151M	-$1.864M	-$1.962M
YoY Change	-20.15%	-4.97%	-7308.79%
Net Earnings / Revenue	-618.39%	-467.08%	-417.87%
Basic Earnings Per Share	-$0.13	-$0.11	-$0.13
Diluted Earnings Per Share	-$0.13	-$0.11	-$132.0K
COMMON SHARES
Basic Shares Outstanding	17.65M shares	15.51M shares	14.86M shares
Diluted Shares Outstanding	16.62M shares	17.65M shares	14.97M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$79.92K	$468.6K	$2.599M
YoY Change	-93.06%	-81.97%	-57.64%
Cash & Equivalents	$1.495K	$8.190K	$36.53K
Short-Term Investments	$78.42K	$460.4K	$2.562M
Other Short-Term Assets	$292.6K	$149.3K	$320.2K
YoY Change	48.19%	-53.37%	213.96%
Inventory	$4.692M	$4.358M	$4.480M
Prepaid Expenses
Receivables	$308.8K	$272.1K	$219.6K
Other Receivables	$500.0K	$500.0K	$500.0K
Total Short-Term Assets	$5.873M	$5.748M	$8.119M
YoY Change	-9.42%	-29.21%	-28.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.874M	$6.855M	$8.208M
YoY Change	-13.7%	-16.48%	-15.48%
Goodwill	$3.014M	$2.189M	$2.189M
YoY Change	37.72%	0.0%
Intangibles			$30.70K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$12.86M	$12.11M	$13.85M
YoY Change	-4.75%	-12.57%	12.25%
TOTAL ASSETS
Total Short-Term Assets	$5.873M	$5.748M	$8.119M
Total Long-Term Assets	$12.86M	$12.11M	$13.85M
Total Assets	$18.73M	$17.85M	$21.97M
YoY Change	-6.26%	-18.72%	-7.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.303M	$3.678M	$2.565M
YoY Change	86.59%	43.35%	16.83%
Accrued Expenses	$2.444M	$592.8K	$1.857M
YoY Change	23.81%	-68.08%	746.23%
Deferred Revenue
YoY Change
Short-Term Debt	$11.79M	$11.04M	$8.642M
YoY Change	23.64%	27.8%	40.3%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.54M	$17.05M	$13.06M
YoY Change	34.17%	30.49%	52.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.573M	$3.573M	$3.480M
YoY Change	1.18%	2.68%	14.36%
Total Long-Term Liabilities	$3.573M	$3.573M	$3.480M
YoY Change	1.18%	2.68%	14.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.54M	$17.05M	$13.06M
Total Long-Term Liabilities	$3.573M	$3.573M	$3.480M
Total Liabilities	$24.82M	$23.42M	$19.71M
YoY Change	21.5%	18.81%	69.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$31.70M	-$29.60M	-$21.50M
YoY Change	30.99%	37.67%
Common Stock	$1.765K	$1.765K	$1.497K
YoY Change	17.98%	17.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.083M	-$5.567M	$2.254M
YoY Change
Total Liabilities & Shareholders Equity	$18.73M	$17.85M	$21.97M
YoY Change	-6.26%	-18.72%	-7.07%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$2.151M	-$1.864M	-$1.962M
YoY Change	-20.15%	-4.97%	-7308.79%
Depreciation, Depletion And Amortization	$424.0K	$422.7K	$409.9K
YoY Change	0.56%	3.13%	-10.95%
Cash From Operating Activities	-$728.9K	-$483.3K	-$729.5K
YoY Change	2.5%	-33.74%	-61.89%
INVESTING ACTIVITIES
Capital Expenditures	$22.85K	$9.350K	-$7.870K
YoY Change	-117.94%	-218.81%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$46.83K
YoY Change		-100.0%	-82.59%
Cash From Investing Activities	-$22.85K	-$9.350K	$38.96K
YoY Change	-82.06%	-124.0%	-85.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	745.0K	427.6K	671.0K
YoY Change	-11.17%	-36.27%	-60.46%
NET CHANGE
Cash From Operating Activities	-728.9K	-483.3K	-729.5K
Cash From Investing Activities	-22.85K	-9.350K	38.96K
Cash From Financing Activities	745.0K	427.6K	671.0K
Net Change In Cash	-6.700K	-65.04K	-19.46K
YoY Change	-2676.92%	234.22%	-137.6%
FREE CASH FLOW
Cash From Operating Activities	-$728.9K	-$483.3K	-$729.5K
Capital Expenditures	$22.85K	$9.350K	-$7.870K
Free Cash Flow	-$751.7K	-$492.7K	-$721.6K
YoY Change	28.78%	-31.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001552189
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q2	us-gaap	Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q2	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q2	us-gaap	Other Liability Noncurrent Related Party Type Extensible Enumeration OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Liability Noncurrent Related Party Type Extensible Enumeration OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain		usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain		usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet		usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet		usd
CY2023Q2	PLSH	Employer Retention Credit EmployerRetentionCredit		usd
CY2022Q2	PLSH	Employer Retention Credit EmployerRetentionCredit		usd
	PLSH	Employer Retention Credit EmployerRetentionCredit		usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain		usd
	PLSH	Non Cash Settlement Of Convertible Note And Accrued Interest NonCashSettlementOfConvertibleNoteAndAccruedInterest		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	PLSH	Repayment Of Notes Payable RepaymentOfNotesPayable		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	PLSH	Conversion Of Preferred Shares To Note Payable ConversionOfPreferredSharesToNotePayable		usd
	PLSH	Issuance Of Common Stock For Services Non Cash IssuanceOfCommonStockForServicesNonCash		usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
CY2022Q4	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q2	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Vested And Exercisable In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionVestedAndExercisableInPeriodWeightedAverageIntrinsicValue		usd
CY2022Q4	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
CY2023Q2	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Vested And Exercisable In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionVestedAndExercisableInPeriodWeightedAverageIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38190
	dei	Entity Registrant Name EntityRegistrantName	Panacea Life Sciences Holdings, Inc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1085858
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5910 S University Blvd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	C18-193
	dei	Entity Address City Or Town EntityAddressCityOrTown	Greenwood Village
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80121
	dei	City Area Code CityAreaCode	800
	dei	Local Phone Number LocalPhoneNumber	985-0515
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17645352	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8190	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6951	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	272090	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	206127	usd
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	500000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	500000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	4357733	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4448725	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	460388	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1107362	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	149295	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113098	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	5747696	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6382263	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3062090	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3242381	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6855283	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7675995	usd
CY2023Q2	us-gaap	Goodwill Goodwill	2188810	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2188810	usd
CY2023Q2	us-gaap	Assets Assets	17853879	usd
CY2022Q4	us-gaap	Assets Assets	19489449	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3677546	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2666076	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2325808	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2090271	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	10829779	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9871803	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	115000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	346671	usd
CY2023Q2	PLSH	Paycheck Protection Loan PaycheckProtectionLoan	99100	usd
CY2022Q4	PLSH	Paycheck Protection Loan PaycheckProtectionLoan	99100	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17047233	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15073921	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2800766	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2987208	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2023Q2	us-gaap	Liabilities Liabilities	23420863	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21633993	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17645352	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17645352	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14965317	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14965317	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	1765	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1497	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23993533	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23760704	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29563134	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25907597	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-5566984	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2144544	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17853879	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19489449	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	399128	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	469472	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1076609	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	935946	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	196314	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	331500	usd
	us-gaap	Cost Of Revenue CostOfRevenue	648186	usd
	us-gaap	Cost Of Revenue CostOfRevenue	697591	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	202814	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	137972	usd
	us-gaap	Gross Profit GrossProfit	428423	usd
	us-gaap	Gross Profit GrossProfit	238355	usd
CY2023Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1131711	usd
CY2022Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1173296	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2399870	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2461111	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	145213	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	204678	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	392626	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	665230	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1276924	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1377974	usd
	us-gaap	Operating Expenses OperatingExpenses	2792496	usd
	us-gaap	Operating Expenses OperatingExpenses	3126341	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1074110	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1240002	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2364073	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2887986	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	366944	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	569985	usd
	us-gaap	Interest Expense InterestExpense	747101	usd
	us-gaap	Interest Expense InterestExpense	1071280	usd
CY2023Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-464719	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-260273	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-646974	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1205077	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	22816	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	22816	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	27598	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	27598	usd
	PLSH	Employer Retention Credit EmployerRetentionCredit	253791	usd
CY2023Q2	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	41531	usd
CY2022Q2	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	58045	usd
	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	101863	usd
	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	116091	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	748	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-790132	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-721799	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1291464	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1856061	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1864242	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1961801	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3655537	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4744047	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1864242	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1961801	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3655537	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4744047	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17645352	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17645352	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14965317	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14965317	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17645352	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17645352	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14965317	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14965317	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2144544	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23097	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	135000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3655537	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-5566984	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3800839	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23097	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1864242	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-5566984	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7102402	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	55000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-159362	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4744047	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2253993	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4180794	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	35000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1961801	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2253993	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3655537	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4744047	usd
	us-gaap	Depreciation Depreciation	845282	usd
	us-gaap	Depreciation Depreciation	818586	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	22816	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-646974	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1205077	usd
	PLSH	Non Cash Settlement Of Convertible Note And Accrued Interest NonCashSettlementOfConvertibleNoteAndAccruedInterest	-74999	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30700	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	38329	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	568219	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	65963	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-24945	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-90992	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	216202	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	36197	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	41823	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1034568	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	982474	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	229386	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	229387	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-797167	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1165500	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	46832	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24570	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17604	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24570	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	29228	usd
	PLSH	Repayment Of Notes Payable RepaymentOfNotesPayable	135000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	118000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	540848	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1075976	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1693875	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	822976	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1153027	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1239	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16755	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6951	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19774	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8190	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	36529	usd
	PLSH	Conversion Of Preferred Shares To Note Payable ConversionOfPreferredSharesToNotePayable	385000	usd
	PLSH	Issuance Of Common Stock For Services Non Cash IssuanceOfCommonStockForServicesNonCash	55000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	168578	usd
CY2023Q2	us-gaap	Area Of Land AreaOfLand	51000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29600000	usd
CY2023Q2	PLSH	Cash And Liquid Stock CashAndLiquidStock	465000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zYKU8ziRb8gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zIvvxVFFUuPa">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Unaudited Condensed Consolidated Financial Statements have been prepared in conformity with US GAAP and required management of the Company to make estimates and assumptions in preparation of these statements. Actual results may differ significantly from those estimates. Significant estimates made by management include but are not limited to the useful life of property and equipment, incremental borrowing rate used in the calculation of right of use asset and lease liability, reserves for inventory, allowance for doubtful accounts, revenue allocations, valuation allowance on deferred tax assets, assumptions used in assessing impairment of long-term assets, assumptions used in the calculation of net realizable value of inventory and fair value of non-cash equity transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	964317	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	870530	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1771177	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1863501	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1598280	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1694574	usd
CY2023Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	460388	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1107362	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1107362	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-646974	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	460388	usd
CY2023Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2023Q2	us-gaap	Goodwill Goodwill	2188810	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2188810	usd
CY2023Q2	PLSH	Packaging Supplies PackagingSupplies	23959	usd
CY2023Q2	PLSH	Customer Advances Payments CustomerAdvancesPayments	330499	usd
CY2022Q4	PLSH	Customer Advances Payments CustomerAdvancesPayments	368065	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	368065	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	24585	usd
	PLSH	Payments Received For Unearned Revenue PaymentsReceivedForUnearnedRevenue	214498	usd
CY2022	PLSH	Payments Received For Unearned Revenue PaymentsReceivedForUnearnedRevenue	412891	usd
	PLSH	Revenue Earned Amount RevenueEarnedAmount	252064	usd
CY2022	PLSH	Revenue Earned Amount RevenueEarnedAmount	69411	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	330499	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	368065	usd
CY2023Q2	PLSH	Shipping And Handling Costs ShippingAndHandlingCosts	32633	usd
CY2022Q2	PLSH	Shipping And Handling Costs ShippingAndHandlingCosts	3782	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	14563	usd
CY2022Q2	us-gaap	Advertising Expense AdvertisingExpense	31312	usd
CY2022Q4	PLSH	Packaging Supplies PackagingSupplies	20120	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6684665	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6410516	shares
CY2022Q4	PLSH	Trading Goods TradingGoods	0	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	4357733	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13223443	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13198873	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6368160	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5522878	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6855283	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7675995	usd
CY2023Q2	us-gaap	Depreciation Depreciation	422728	usd
	us-gaap	Depreciation Depreciation	845282	usd
CY2022Q2	us-gaap	Depreciation Depreciation	409895	usd
	us-gaap	Depreciation Depreciation	818586	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4448725	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-12-31
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-12-31
CY2023Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3062090	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3242381	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3168620	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3347331	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2800766	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2987208	usd
CY2023Q2	PLSH	Shortterm Portion Of Operating Lease Liability ShorttermPortionOfOperatingLeaseLiability	367854	usd
CY2022Q4	PLSH	Shortterm Portion Of Operating Lease Liability ShorttermPortionOfOperatingLeaseLiability	360123	usd
CY2023Q2	PLSH	Unpaid Balance UnpaidBalance	1957947	usd
CY2022Q4	PLSH	Unpaid Balance UnpaidBalance	1730136	usd
CY2023Q2	PLSH	Operating Leases Liability Current OperatingLeasesLiabilityCurrent	2325801	usd
CY2022Q4	PLSH	Operating Leases Liability Current OperatingLeasesLiabilityCurrent	2090259	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.030	pure
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	114693	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	114693	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	229386	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	229386	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	227811	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	460178	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	464780	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	469427	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	474122	usd
CY2023Q2	PLSH	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1451002	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3547320	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	378700	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3168620	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	346854	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.80
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M25D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	205000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.21
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	551854	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.84
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y11M8D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	551854	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.84
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y11M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1117092	shares
CY2022Q4	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare	2.02
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1117092	shares
CY2023Q2	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare	2.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y6M21D
CY2023Q2	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	1117092	shares
CY2023Q2	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice	2.02
	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P3Y6M21D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	107993	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1793483	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	592752	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	282869	usd

Files In Submission

Name	View Source	Status
0001493152-23-028898-index-headers.html	Edgar Link	pending
0001493152-23-028898-index.html	Edgar Link	pending
0001493152-23-028898.txt	Edgar Link	pending
0001493152-23-028898-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plsh-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
plsh-20230630_cal.xml	Edgar Link	unprocessable
plsh-20230630_def.xml	Edgar Link	unprocessable
plsh-20230630_lab.xml	Edgar Link	unprocessable
plsh-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh

2023 Q3 Form 10-Q Financial Statement

#000149315223028898 Filed on August 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSH Panacea Life Sciences Holdings Inc Stock $plsh

2023 Q3 Form 10-Q Financial Statement

#000149315223028898 Filed on August 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh